Alvotech announced that the U.S. Food and Drug Administration has issued a complete response letter for Alvotech’s Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira®.
Alvotech announced that the U.S. Food and Drug Administration has issued a complete response letter for Alvotech’s Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira®.